Impact BioMedical Inc. (IBO)
Impact BioMedical Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Houston, TX, US. The stock last traded at $0.43, up 0.00% on the session, giving a market capitalisation of $46.4M. On trailing twelve-month figures it carries a trailing P/E of -4.25, a net margin of 2254.3%. Its beta of 2.73 implies it has historically moved more than the broad market.
Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule electrophilically enhanced polyphenol compounds with potential applications in treating cancer, inflammatory diseases, and neurological conditions. Additionally, "Laetose" technology, a unique blend of sugar and inositol, is designed to counteract the inflammatory and metabolic responses usually triggered by sugar consumption. Impact BioMedical also creates "functional fragrance formulations," which are a series of fragrances incorporating specialized botanical ingredients for antimicrobial purposes, or as active additives in items like insect repellents, cleaning products, personal care items, and fabrics. Rounding out its offerings is the "Equivir/Equivir G" technology, a distinctive mix of polyphenols that has exhibited antiviral properties, suitable for use in health supplements and medications.
Impact BioMedical Inc. is most often compared with the following Healthcare names: